Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,065 DKK | +1.98% | +3.10% | -4.18% |
05-15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
05-15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.18% | 19.43B | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B | |
+319.18% | 8.6B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating